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Background Plasma exchange (PEX) is a life-saving therapeutic procedure in
patients with thrombotic thrombocytopaenic purpura (TTP) and other thrombotic
microangiopathic anaemias (TMAs). However, it may be associated with signiﬁ-
cant complications, exacerbating the morbidity and mortality in this patient
group.
Study Design and Methods We reviewed all PEX procedures over a 72-month
period, following the exclusive introduction of solvent–detergent double viral-
inactivated plasma in high-volume users, such as TTP, in the United Kingdom
(UK). We documented allergic reactions to plasma, citrate reactions, complica-
tions relating to central venous access insertion and venous thrombotic events
(VTE) in 155 patient episodes and >2000 PEX procedures.
Results The overall complication rate was low. Allergic plasma reactions
occurred in 645% of the cohort with only one episode of acute anaphylaxis.
Similarly, VTEs were 645%, not signiﬁcantly greater than in medical patients
receiving thromboprophylaxis, despite added potential risk factors in TTP. Citrate
reactions were the most frequent complication documented, but toxicity was sig-
niﬁcantly reduced by administration of further calcium infusions during the PEX
procedure. There were no serious central line infections and no catheter thrombo-
sis.
Conclusion Our data conﬁrms that PEX continues to be a life-saving procedure
in the acute TTP setting and, the procedure was not associated with an increased
mortality and limited morbidity.
Key words: allergic reactions, central venous access, citrate reactions, plasma
exchange, thrombotic thrombocytopaenic purpura, venous thrombotic events.
Introduction
Thrombotic thrombocytopaenic purpura (TTP) is an acute
life-threatening disorder associated with thrombocytopae-
nia, microangiopathic haemolytic anaemia and evidence
of organ ischaemia. It results from a deﬁciency of the
enzyme ADAMTS 13, important in cleavage of ultralarge
von Willebrand factor multimers [1–3]. Reduced ADAMTS
13 levels as in TTP are associated with the development
of microvascular thrombi. Untreated, an acute presenta-
tion of TTP has an associated mortality of >90%. Thera-
peutic apheresis and the use of plasma have been the
mainstay of treatment of acute TTP for nearly half a cen-
tury and have had the greatest beneﬁt on mortality
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161outcomes. The beneﬁt of PEX over plasma infusion has
been demonstrated, but the mortality of acute TTP epi-
sodes remains between 10 and 20% [4].
Since 1 January 2006, the UK Department of Health
have sourced non-UK, virally inactivated plasma for all
children born after 1 January 1997 and all high-volume
plasma users, including patients with TTP. For patients
with TTP, solvent–detergent fresh-frozen plasma (SD-
FFP), Octaplas (Octapharma, UK) a pooled plasma product
that has undergone double viral inactivation is the pre-
ferred choice (DH Gateway reference 5999, 2006).
Although generally well tolerated, there are a series of
potential complications associated with PEX. There have
been a number of reports detailing adverse events related
to line insertion, the plasma product and complications
associated with it [5,6], resulting in death or morbidity in
some cases. We have therefore undertaken a review of
PEX procedures, plasma complications and adverse reac-
tions because Octaplas has been exclusively used in the
UK for patients with TTP. We have previously reported
lower reaction rates with viral-inactivated plasma com-
pared with standard fresh-frozen plasma (FFP)/cryosuper-
natant [7] and wanted to conﬁrm this has remained
consistent since exclusive use of Octaplas in this group of
high-volume users.
Methods
Within a single institution, we reviewed 155 sequential
patient episodes [deﬁned as inpatient admissions with
acute presentation of thrombotic microangiopathic anae-
mias (TMA), speciﬁcally TTP] over a 72-month period,
January 2006–December 2012. Our institution is a large
tertiary referral centre for TTP but which also accepts and
treats other thrombotic microangiopathies requiring treat-
ment by therapeutic apheresis.
Cases were identiﬁed from hospital electronic records
and case notes, and consent was given by all patients
(MREC: 08/H0810/54 and MREC: 08/H0716/72). For all
cases, we identiﬁed complications associated with our use
of PEX. We recorded patient demographics, disease char-
acteristics, laboratory parameters, red blood cell usage
and the number of central venous access (CVA) lines
inserted. Furthermore, we documented reactions to
SD-FFP, citrate toxicities, venous thrombotic events (VTE)
and the incidence of CVA-related line sepsis. Reactions to
SD-FFP and ACD-A were classiﬁed and graded based on
an adapted grading system [8].
Within our institution, all PEX procedures were carried
out using centrifugation apheresis machines, either the
COBE Spectra or Spectra Optia (Terumo BCT, Lakewood,
CO, USA). The ﬁrst PEX procedure routinely exchanges 15
plasma volumes as per BCSH guidelines [9]. The volume of
the replacement ﬂuid required is calculated by multiplying
the patients’ weight by 60 ml for a 15 plasma volume and
by 40 ml for a 1 plasma volume procedure.
We use ACD-A as anticoagulant for all PEX proce-
dures. In an effort to minimize citrate reactions, it is local
policy to administer calcium gluconate 22 mmol in
100 ml of normal saline over 15 min upon initiation of
PEX, followed by calcium gluconate 004 mmol/kg/h for
the remainder of the procedure.
All cases of VTE and their location are recorded fol-
lowing clinical assessment and vascular or radiological
interventions. Day of PEX treatment, relation to CVA and
platelet count were noted, as was initiation of appropriate
therapy for the proven VTE.
In patients with CVA lines inserted, days in situ and
subsequent line changes are closely monitored. When
patients with TTP are ﬁrst admitted, CVA lines are
required for a variety of reasons, such as poor peripheral
access and ﬂuctuating neurological status. Femoral
venous access is commonly obtained, as this is associated
with reduced potential insertion risks and reduces the
time delay to commence PEX.
However, femoral access is associated with a higher
risk of infection [10]. Femoral lines are replaced with
neck (subclavian or internal jugular vein) lines within
48–72 h; minimizing infections is particularly important,
as infections in patients with TTP can lead to a TTP exac-
erbation [7]. The documented infections are highlighted,
day diagnosed and bacteria isolated (Table 6).
Results
Over the 72-month period, a total of 2067 PEX proce-
dures were performed in the 155 patient episodes, with
each PEX procedure time ranging between 2 and 4 h.
Patient demographics and admission characteristics are
shown in Table 1.
There were 108 females and 47 males presenting with
acute TTP episodes, which is in keeping with 2:1 female
preponderance. In total, 147 patient episodes were con-
ﬁrmed TTP (95%), of which 13 episodes (8%) were TTP
relapses and 16 episodes (10%) a deﬁned precipitant was
identiﬁed, including HIV (N = 7), pancreatitis (n = 3),
congenital TTP (N = 6). The remaining cases were ‘other’
TMAs including aHUS or pregnancy-associated microan-
giopathies.
The overall risk of complications related to PEX is
highlighted in Table 2.
Incidence of VTE in acute TTP
Venous thrombotic events was documented in 10 of 155
(645%) patient episodes. These included six cases of
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162 S. McGuckin et al.pulmonary embolism (PE) and three cases of below-knee
deep vein thrombosis (DVT) and one case of above-knee
DVT. There were no episodes of line-associated thrombo-
sis. Platelet count (Table 3) on the day of documented PE
ranged from 7 to 292 9 10
9/l. The day of the docu-
mented PE ranged from Day 2 to 28. Platelet count on
the day of documented DVT ranged from 86 to
243 9 10
9/l, and they were diagnosed between days 6
and 12 from TTP diagnosis.
Allergic reactions to SD-FFP
Within the cohort of 155 patient episodes, 10 (645%)
plasma reactions were reported. Eight females and two
males had plasma reactions (Tables 4 and 5). Reactions
included minimal signs and symptoms such as hives,
itchy eyes to the more serious complications of chest,
throat tightness to one major episode of stridor, which
resulted in the administration of epinephrine and subse-
quent emergency transfer to the intensive care unit (ICU)
for monitoring purposes. A full investigation excluded
IgA deﬁciency or any other obvious cause for the reac-
tion. A different batch of Octaplas was administered for
all further PEX procedures, with premedication of chlor-
phenamine given with subsequent PEX procedures until
remission without incident. We had no reported instances
of transfusion-related associated lung injury or viral/
infectious transmission.
Reaction to citrate
Within the cohort of 155 patient episodes reviewed, 15
(96%) had documented citrate (ACD-A) reactions, affect-
ing 12 females and three males. The majority of ACD-A
reactions were experienced by the patients during their
initial PEX procedures, typically between days 1 and 4,
with one patient experiencing reactions later in the
course of their treatment (on D10 and D15). Symptoms
experienced and reported by the patients ranged from: lip
tingling (n = 5), pruritus (n = 2), nausea/lightheadedness
(n = 6), chest and leg twitching (n = 2).
When reactions were reported by the patient during
PEX, the inlet ﬂow rate on the apheresis machine was
initially lowered and if symptoms did not resolve, repeat
boluses of 22 mmol of calcium gluconate IV were
administered. However, no PEX procedures had to be per-
manently stopped.
Complications related to central venous access
Central venous access is the preferred mode for PEX pro-
cedures for patients, as each PEX procedure can last
between 2 and 4 h, therapy is required daily (or
Table 1 Demographics and admission characteristics of patients treated
with plasma exchange (PEX) for microangiopathic haemolytic anaemia/
thrombotic microangiopathic anaemias
Total n = 155
Female: Male 108:47 (2:1)
Mean age (years): Female (range) 439 (13–85)
Mean age (years): Male (range) 492 (19–87)
Ethnicity
White 103
Afro/Caribbean 28
Other 24
Median presenting Hb, g/dl (range) 9 (48–151)
Median presenting platelets, 910
9/l (range) 16 (2–183*)
Median presenting LDH, IU (range) 1226 (227–5000)
Median length of stay, days (range) 14 (1–87)
Median number of PEX procedures (range) 11 (1–57)
Median number of transfused red cells:
Females (range)
6( 0 –26)
Median number of transfused red cells:
Males (range)
6( 0 –29)
*Patient transferred from abroad-with thrombotic thrombocytopaenic
purpura relapse-having been treated pre transfer and platelet count nor-
mal on return.
Table 2 Summary of complications associated with plasma exchange
procedures
Total (N) Overall incidence (%)
Venous thrombotic events 10 645
Allergic plasma reactions 10 645
Citrate reactions 15 96
Line associated infections 13 83
Table 3 Classiﬁcation of position and platelet count when venous
thrombotic events diagnosed
Event Day of event Platelet count (310
9/l)
BK DVT 6 243
61 1 8
81 0 0
AK DVT 12 86
PE 2 7
37 7
73 9
13 62
13 292
28 148
BK DVT, below knee deep vein thrombosis; AK DVT, above knee deep vein
thrombosis; PE, pulmonary embolus.
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Complications of PEX in TTP 163sometimes twice daily) and avoids the need for repeated
venipuncture. In our cohort, there were a median of 11
PEX procedures per patient episode, range 1–57. How-
ever, 1096% (n = 17) of the patient episodes had all PEX
procedures carried out using peripheral access only.
Eighty-one femoral lines were initially sited upon
admission compared with 55 neck lines. A total of 267
CVA lines were inserted for PEX for the remaining 138
patients requiring procedures. Of these, femoral lines
(n = 94) were in situ for a median of 35 days (range
1–5 days) and neck lines, (n = 173) for a median of
8 days (range 1–10 days). All CVA lines were inserted
either in an ICU setting by anaesthetists, theatre or in in-
terventional radiology.
There were 13 (89%) documented episodes of line sep-
sis in seven female patients and four male patients
(Table 6). One female patient had two documented line
infections: one with a femoral line sited on admission
and a further episode with a subsequent neck line. One
male had two documented line infections both associated
with neck lines. All documented line sepsis episodes were
treated with appropriate antibiotics and where possible,
the line was replaced. There were no episodes of bleeding
associated with line insertion, and no platelets were
needed to cover any insertion procedure. Furthermore,
there were no episodes of complications associated with
line insertion such as pneumothorax or haemothorax.
Red cell usage
Within our 155 patient episodes, a median of 6 units of
red cells was transfused for both males (range 0–29 units)
and females (range 0–26 units). The two patients who
required 29 and 26 units of blood respectively, both had
prolonged admissions which required intensive
transfusion support over a period of several weeks.
Table 4 Classiﬁcation of complications of therapeutic plasma exchange (PEX)
Grade of reaction Effect of reaction Plasma: manifestation and intervention Citrate: manifestation and intervention
Grade 1: Mild No medical intervention; procedure
not delayed
Localised reaction (<25% skin affected):
e.g. skin
rash, hives: inlet rate reduced
Tingling, nausea: PO Ca
+
followed by IV Ca
+
Grade 2: Moderately
severe
Not life threatening; medical
intervention and/or delay of procedure
required; no procedures terminated
Moderate reaction (>25% skin affected)
e.g. skin rash, hives: IV bolus of Piriton
and Hydrocortisone
Chest symptoms, (heaviness):
IV Ca
+ Gluconate, inlet rate reduced
Grade 3: Severe Life threatening and/or procedure
terminated
Anaphylaxis: IV bolus of Adrenalinine
and nebulized salbutamol. Transfer
to ITU
Grade 4: Fatal Death during or associated with PEX Cardiopulmonary resuscitation
ITU, Intensive therapy unit; IV, intravenous.
Table 5 Allergic reactions to plasma
Episode
number Sex
Type of
reaction
Grading of
reaction Intervention
1 F Facial itch 1 Inlet rate reduced
2 F Facial itch,
wheeze
2 Nebulized salbutamol
3 F Hives 2 IV Piriton
4 F Stridor 3 Adrenaline, H&P
5 F Itchy eyes 1 Inlet rate reduced
6 F Hives 2 IV Piriton
7 F Lip swelling 2 H&P, nebulized salbutamol
8 F Wheeze 2 H&P, nebulized salbutamol
9 M Itchy eyes,
chest
Tightness
2 IV Piriton
10 M Hives 2 IV Piriton
IV, Intravenous; H&P, hydrocortisone and piriton.
Table 6 Central venous line related infections
Episode Line site
Day of
Sepsis Organism identiﬁed
1 Neck 10 CNS
2 Femoral 5 Escherichia coli
3 Femoral 5 CNS
4 Femoral 2 CNS
5 Femoral 1 Staphylococcus aureus
6 Neck 4 Staphylococcus aureus
7 Femoral 4 CNS
8 Neck 7 CNS
9 Neck 2 CNS
10 Neck 8 CNS
11 Neck 1 Enterococcus Faecalis,
Alpha-haemolytic Streptococcus, CNS
12 Neck 2 Staphylococcus epidermis
13 Neck 5 Acute Haemolytic Streptococcus
CNS, Coagulase negative staph.
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Although PEX remains a life-saving therapeutic proce-
dure in TTP and other TMAs [8], its use is associated with
a series of potential complications. This review of thera-
peutic PEX procedures encompassed a large cohort of
patients and examined complications of therapy. We have
documented low rates of reactions to virally inactivated
plasma SD-FFP (Octaplas), citrate reactions and complica-
tions relating to line infections, which may precipitate
exacerbation of TTP. We have not had any patient deaths,
either in this cohort or previously published, due to PEX
or line insertion [7]. Furthermore, the rate of VTEs is
probably between 5 and 10% for symptomatic cases and
not exclusively related to PEX, or the plasma used.
The incidence of VTE has not been highlighted speciﬁ-
cally in the TTP literature. In our cohort, there were 10 cases
of clinically diagnosed VTE, conﬁrmed radiologically with
an incidence of 645%. Although the overall risk of VTE
may be perceived to be higher in patients with TTP, the risk
for untreated medical patients is between 10 and 20%. Fur-
thermore, using thromboprophylaxis (enoxaparin 40 mg s/
c daily), the VTE rate in medical patients was reduced to
55% compared with 149% with placebo (no treatment)
[11]. Therefore, the rate in our cohort would be in keeping
with medically treated patients. There has been a suggestion
that VTEs could be precipitated by lower levels of protein S
in Octaplas compared with standard FFP. However, review
of the cases and follow-up of further procedures on com-
paring Octaplas with standard FFP, there was no greater
risk, which has been reduced further by prophylactic mea-
sures subsequently introduced to prevent VTEs [7].
Within the UK, thromboprophylaxis has become a
requirement for all eligible hospitalized patients. In
patients with TTP, graduated elastic compression stock-
ings (TEDs) are prescribed on admission. LMWH thrombo-
prophylaxis, such as dalteparin 2500 IU subcutaneously
BD, is administered once the platelet count is >50 9 10
9/
l. Within the presented cohort, VTE occurred at a range
of platelet counts, including cases with low platelet
counts (<10 9 10
9/l) and in the normal range. Therefore,
VTE could not be convincingly associated speciﬁcally
with PEX and probably reﬂects multiple risk factors,
including that TTP is a prothrombotic condition, immo-
bility, use of steroids and patients’ weight.
With the sole administration of solvent–detergent
fresh-frozen plasma, Octaplas, in therapeutic PEX, reac-
tions, although still documented, are low in occurrence.
There may have been underreporting of minor reactions;
however, major reactions remain signiﬁcantly reduced
compared with data from standard FFP. Comparing two
different plasma products in therapeutic exchange proce-
dures, cryosupernatant was associated with reactions in
93% of PEX procedures, compared with 31% of those
using Octaplas [7]. A further review of 4857 PEX proce-
dures from 509 patients documented 231 adverse reac-
tions utilizing different replacement ﬂuids. Nineteen
patients, with thrombotic microangiopathy, FFP used in
594 therapeutic apheresis procedures, documented, 5
(01%) anaphylactic reactions [12]. A comparison of stan-
dard FFP and cryosupernatant in patients with TTP sug-
gests reactions occur in 65% of patients, which is
unsurprising given the volumes required and length of
time of therapy [13].
The Oklahoma group, in their latest review, reported 20
cases of plasma reactions out of a total number of 302
complications. Of the 20 cases, nine would be classiﬁed
as grade 3, with anaphylaxis in one resulting in cardiac
arrest, and ﬂuid overload in another necessitating PEX
being stopped and the patient intubated and ventilated.
Furthermore, the authors suggested that reactions and
complications have decreased with changes in manage-
ment of patients, including less PEX to remission, with
the use of adjunct immunosuppressive therapies [6].
Toxicity related to ACD-A anticoagulant solutions are
frequently encountered. Modern apheresis equipment per-
mits whole blood processing rates that are faster than
those used in earlier case studies. This can inevitably
increase the risk of citrate toxicity experienced by
patients. Within the literature, it is reported that in a
minority of PEX procedures, citrate toxicity can cause
discomfort to patients and occasionally can lead to
changes and abnormalities from baseline electrocardio-
graphic readings [14]. In our cohort, the majority of
ACD-A reactions were experienced in initial PEX proce-
dures. However, the overall rates are low with current
calcium replacement protocols.
Utilization of CVA has increased dramatically in recent
years. Whilst they are undoubtedly of extreme importance
in the carrying out the PEX procedures, they represent a
foreign body with direct access to the blood stream that
can serve as a port of entry or a reservoir for infection.
Central line blood stream infections are associated with
high morbidity, mortality and cost [15].
Complications are reported within the literature with
CVA and with associated infections. CVA was utilized in
23% of patients and two patients developed a pneumo-
thorax as a direct result of CVA insertion [16]. The
Oklahoma group have reported seven deaths. Pulmonary
haemorrhage leading to death occurred in three cases
with death resulting from systemic infection in four cases.
There were 22 episodes of thrombosis, and 17 resulted
in catheter obstruction where catheters had to be
removed [6].
Within our patient cohort, we have had no deaths, no
haemothorax or pneumothorax and no line-associated
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Complications of PEX in TTP 165thrombosis. Indeed, stricter adherence to our protocol of
removing femoral CVA within 48 h of insertion and
changing neck lines weekly would have reduced the
infection rate further. This is not always possible as a
patient’s requirement for PEX outweighs line changes on
some occasions. However, the beneﬁt of this practice at
reducing line infections has been demonstrated [7]. Fur-
thermore, line-insertion protocols, strict aseptic proce-
dures and manipulation of lines using aseptic non-touch
technique (ANTT) [17], have all contributed to the low
infection rates.
In conclusion, we have presented data on the compli-
cation rates of therapeutic PEX primarily in patients with
TTP, for whom treatment is intensive to achieve remis-
sion. Overall, the rates of complications are low, speciﬁ-
cally for plasma reactions and VTEs. Line complications
including sepsis have been reduced, and citrate reactions
appear to be the most frequent event documented, with
current infusion protocols. Therefore, therapeutic PEX
appears to be a safe procedure, and the iatrogenic mor-
bidity in this patient group has improved.
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